Company Name:ChemoCentryx, Inc.
CEO: Thomas J. Schall

Sector: Health Technology
Industry:Biotechnology

Exchange: NASDAQ

Country: US

Description: ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.


Key numbers

Market Capitalization:3530393100
Shares Outstanding: 67054000
Float: 50324161
Next Earning Date:2020-08-06
TTm EPS: -1.0992
TTm Dividend Rate:
200 days moving average:41.25
50 days moving average: 58.42
One day percent Change: -0.79



2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,